文章摘要
何俐莹,陶雪莹,岑超.复方木芙蓉涂鼻软膏治疗变应性鼻炎的临床疗效及其网络药理学研究[J].安徽医药,2023,27(1):174-179.
复方木芙蓉涂鼻软膏治疗变应性鼻炎的临床疗效及其网络药理学研究
Efficacy of Mufurong nasal ointment in treating allergic rhinitis and analysis of its mechanism based on network pharmacology
  
DOI:10.3969/j.issn.1009-6469.2023.01.038
中文关键词: 鼻炎,变应性  复方木芙蓉涂鼻软膏  白三烯 E4  白细胞介素类  基因本体  网络药理学
英文关键词: Rhinitis,allergic  Mufurong nasal ointment  Leukotriene E4  Interleukins  Gene ontology  Network pharmacology
基金项目:
作者单位
何俐莹 重庆医科大学附属妇女儿童医院重庆市妇幼保健院眼耳鼻喉科重庆 401147 
陶雪莹 重庆医科大学附属妇女儿童医院重庆市妇幼保健院眼耳鼻喉科重庆 401147 
岑超 重庆医科大学附属妇女儿童医院重庆市妇幼保健院眼耳鼻喉科重庆 401147 
摘要点击次数: 872
全文下载次数: 231
中文摘要:
      目的探讨复方木芙蓉涂鼻软膏治疗变应性鼻炎( AR)的临床疗效,并结合网络药理学探索其治疗 AR的作用机制,明确其作用靶点及信号通路。方法选择重庆市妇幼保健院 2019年 10月至 2020年 12月确诊为 AR的病人 130例,使用随机数字表法分为对照组和观察组,每组均 65例,对照组采用丙酸氟替卡松鼻喷雾剂常规治疗,观察组采用复方木芙蓉涂鼻软膏,均治疗 4周。比较两组治疗前后尿中白三烯 E(4leukotriene E4,LTE4)水平、肿瘤坏死因子 -α(TNF-α)、白细胞介素 -4(IL-4)、白细胞介素 -6(IL-6)、白细胞介素 -12(IL-12)水平以及总有效率。同时通过中药系统药理学数据库和分析平台( TCMSP)以及多个数据库联合检索筛选复方木芙蓉涂鼻软膏活性成分 -作用靶点,采用 Rversion 3.6.2软件及 Cytoscape 3.7.1软件构建复方,木芙蓉涂鼻软膏治疗 AR的成分 -作用靶点 -通路网络,最后利用 R语言中 Bioc Manager包进行基因本体功能注释及京都基因与基因组百科全书(KEGG)通路富集分析。结果观察组总有效率(89.23%)明显高于对照组总有效率( 72.31%),经过 4周治疗后,两组尿中 LTE4水平均显著低于治疗前,且两组 TNF-α、IL-4、IL-6、IL-12表达水平均出现显著下降,观察组下降程度较对照组较大,均差异有统计学意义( P<0.05)。经筛选得到槲皮素、山柰酚等 9个主要活性成分,并得到复方木芙蓉涂鼻软膏治疗 AR的关键靶点为 IL-6、血管内皮生长因子 A(VEGFA)、丝裂原活化蛋白激酶 1(MAPK1)、蛋白激酶( AKT1)等,关键通路为低氧诱导因子 -1(HIF-1)信号通路、 TNF信号通路、磷脂酰肌醇 3-激酶(PI3K)和 AKT/蛋白激酶 b(PI3K-Akt)信号通路以及晚期糖基化终末产物 糖基化终末产物受体( AGE-RAGE)信号通路等。结论复方木芙蓉涂鼻软膏可作用于 VEGFA、IL-6、AKT1、MAPK1等靶点,调控 HIF-1、TNF、PI3K-Akt等信号通路,从而降低或抑制变应性鼻炎 TNF-α、IL-4、IL-6、IL-12等炎性因子水平,达到治疗效果。
英文摘要:
      Objective To explore the therapeutic efficacy of compound Mufurong nasal ointment (MNO) in treating allergic rhinitis,and to study the mechanism in treating allergic rhinitis and explore the action target and signal pathway of MNO for allergic rhinitis bynetwork pharmacology.Methods A total of 130 patients diagnosed with AR in Chongqing Health Center for Women and Childrenfrom October 2019 to December 2020 were included in the study and assigned into control group and observation group using randomnumber table method; there were 65 cases in each group. The control group was treated with Fluticasone while the observation groupwas treated with MNO, both for 4 weeks. observe comparison was made of the levels of leukotriene E4 (LTE4), tumor necrosis factorα (TNF-α), interleukin-4 (IL-4), interleukin-6 (IL-6) and interleukin-12 (IL-12) in urine and the total effective rate before and after treatment. At the same time, the study used Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP)and other databases to screen MNO active components and TCM targets, then the Rversion 3.6.2 software and Cytoscape 3.7.1 softwarewere used to construct the network of component, action target and pathway for treating AR. Finally, gene ontology function annotationand Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed using bioc manager package inthe R language.Results The total efficiency of the observation group (89.23%) was significantly higher than that of the control group(72.31%). After 4 weeks of treatment, the levels of LTE4 in urine of the two groups were significantly lower than those before treatment, and the expression levels of TNF-α,IL-4, IL-6, and IL-12 of the two groups decreased significantly; the decrease in the observationgroup was greater than that in the control group, and the difference was statistically significant (all P<0.05). Nine active ingredients, including quercetin and kaempferol, were obtained. The key targets were also identified, including IL6, vascular endothelial growth factorA (VEGFA), mitogen-activated protein kinase 1 (MAPK1), and protein kinase 1 (AKT1). The key pathways were hypoxic inducible fac tor-1 (HIF-1) signaling pathway, TNF signaling pathway, Phosphatidylinositol 3-kinase and AKT/protein kinase b (PI3K-Akt) signaling pathway, and advanced glycosylation end products-receptor for advanced glycosylation end products (AGE-RAGE) signaling pathway. Conclusion Compound MNO can regulate the signaling pathways of HIF-1, TNF and PI3K-Akt by targeting VEGFA, IL-6, AKT1 and MAPK1, so as to reduce or inhibit the inflammatory factors of TNF-α, IL-4, IL-6, and IL-12 to achieve efficacy.
查看全文   查看/发表评论  下载PDF阅读器
关闭

分享按钮